Huahui Health Ltd.
↗Beijing, China
Huahui Health Ltd. (HHHbio) is a clinical-stage biotechnology company founded in 2015, headquartered in Beijing, China. The company specializes in the discovery and development of innovative therapies for viral hepatitis (specifically HBV and HDV), hepatology, and oncology, leveraging expertise in disease biology and protein engineering.
Their pipeline includes first- and best-in-class candidates, most notably Libevitug (HH-003), a first-in-class anti-PreS1 human monoclonal antibody for chronic hepatitis D and B, which has received Breakthrough Therapy Designation from the FDA and conditional approval in China.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Founded:2015
Ownership:private
Status:operating
FUNDING
Stage:Series B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Libevitug/HH-003 approved in China)
Modalities:Monoclonal Antibody, Small molecule, Antibody-drug Conjugate (ADC)
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
COMPETITION
Position:Emerging
LEADERSHIP
Key Executives:
Bin Chen - CEO
Wenhui Li - Chairman of the Board
Bin Ye - Chief Scientific Officer
Scientific Founders:Wenhui Li
LINKS
Website:hhhbio.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Huahui Health Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Huahui Health Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.